Physicians “Cautiously Open” To OTC Statins – NLA Survey
This article was originally published in The Tan Sheet
Executive Summary
More than half the physician respondents in a National Lipid Association survey said it is "important" that FDA look into the potential of an OTC statin for patients at moderate risk for coronary heart disease
You may also be interested in...
J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group
J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands